Granules India Ltd
Granules India Q2 FY27: Capex ₹2,000 Cr
Q2 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY27 call signalled
2 of 3 strong
The short version
Granules aims to achieve approximately $50 million USD in annual revenue run rate within three years (around FY29). Granules expects a positive translation of gross margin improvements (up 15 percentage points) into EBITDA margin growth going forward.
From Granules India Ltd's Q2 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Granules aims to achieve approximately $50 million USD in annual revenue run rate within three years (around FY29).
- Long-term target is to cross the $100 million USD revenue size within five years.
- Growth driven by four engines: controlled substances, complex generics, oncology portfolio, and peptide CDMO.
- Expansion into specialty and institutional segments in the US, with first specialty product launch expected in FY29.
- Geographic diversification planned with increased presence in Europe, Latin America, and other strategic markets by FY30.
- Increase US ANDA filing rate from 6-10 per year to 10-15 per year to support product pipeline extension globally.
- Focus on higher-value products and early market opportunities to improve earnings quality and operating leverage.
2 more points from Granules India Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Granules India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years.
- Capex will support complex generics pipeline, oncology pipeline, peptide CDMO, US operations, manufacturing, and R&D infrastructure.
- Investments will also be made in digitalization, AI, manufacturing excellence, and quality systems to enhance productivity, resilience, and competitiveness.
- The capex follows a disciplined, milestone-based approach aligned with development progress, regulatory milestones, customer commitments, and commercial opportunities.
- Granules is actively looking for inorganic opportunities, particularly on the peptide side or vertical expansions, maintaining discipline in selection.
- Investment focus areas include the Peptide CDMO platform, with ambitions to become a meaningful mid-size global CDMO.
2 more points from Granules India Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Granules India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Granules India Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Granules India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.5K Cr, net profit ₹202 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Granules India Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Accent Microcell Ltd (Q2 FY27)
. Key investor presentation takeaways from Accent Microcell Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Arthneeti Pro · Annual
Granules India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Granules India Ltd Q2 FY27 results?
Granules aims to achieve approximately $50 million USD in annual revenue run rate within three years (around FY29). Granules expects a positive translation of gross margin improvements (up 15 percentage points) into EBITDA margin growth going forward.
What is Granules India Ltd share price analysis?
Granules India Ltd currently shows a below-average growth signal. The stock trades at a P/E of 34.6 with a market cap of ₹22,514 Cr. Investors should review the full earnings analysis for detailed insights.
Is Granules India Ltd planning capital expenditure?
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years.
Keep Granules India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.